Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms

Clinical Cancer Research

Volumn 8, Issue 3, 2002, Pages 718-728

  Sandor, Victor ^a   Bakke, Susan ^b   Robey, Robert W ^b   Kang, Min H ^b   Blagosklonny, Mikhail V ^b   Piekarz, Richard L ^b   Figg, William D ^b   Fojo, Antonio Tito ^b   Bates, Susan E ^b   Tucker, Eben ^c   Goldspiel, Barry ^c   Bender, Jonathon ^d   Brooks, Rebecca ^d   Chan, Kenneth K ^d   Balcerzak, Stanley P ^d  

^a MCGILL UNIVERSITY   (Canada)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CLINICAL CENTER   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEPSIPEPTIDE; FR 901228; HEART ENZYME; HISTONE DEACETYLASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; ELECTROCARDIOGRAM; FATIGUE; FEMALE; HEART ARRHYTHMIA; HEART VENTRICULOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM TOLERATED DOSE; NAUSEA; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; DEPSIPEPTIDES; ELECTROCARDIOGRAPHY; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NAUSEA; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEUTROPENIA; PEPTIDES, CYCLIC; THROMBOCYTOPENIA;

EID: 0036301281     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physicochemical and biological properties, and antitumor activity
2. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice
3. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells
4. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute Drug Screen
5. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor
6. Histone deacetylases, transcriptional control, and cancer
7. Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression
8. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation
9. Genes modulated by histone acetylation as new effectors of butyrate activity
10. FR901228 causes mitotic arrest but does not alter microtubule polymerization
11. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228
12. Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells
13. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells
14. A subnanogram API LC/MS/MS quantitation method for depsipeptide FR901228 and its preclinical pharmacokinetics
15. Sodium butyrate inhibits histone deacetylation in cultured cells
16. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
17. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia
18. Role of the histone deacetylase complex in acute promyelocytic leukaemia
19. Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: A new approach to antileukemia therapy
20. Expression of a drug resistance gene in human neuroblastoma cell lines: Modulation by retinoic acid-induced differentiation
21. Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents
22. Modulation of EGF receptor expression by differentiating agents in human colon carcinoma cell lines
23. Cardiovascular effects of phenothiazines
24. Randomized, double-blind comparison of a prochlorperazine-based versus a metoclopramide-based antiemetic regimen in patients undergoing autologous bone marrow transplantation
25. Effects of granisetron with doxorubicin or epirubicin on ECG intervals
26. Cardiac dysrhythmias associated with the intravenous administration of ondansetron and metoclopramide
27. Selection of drugs to treat gastro-oesophageal reflux disease: The role of drug interactions
28. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors
29. Phase I trial of interleukin-2 and high-dose arginine butyrate in metastatic colorectal cancer
30. Modulation of DAB389IL-2 (ONTAK) cytotoxicity in leukemia and lymphoma by arginine butyrate and all-trans retinoic acid
31. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma
32. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report
33. Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by nonretinoid agents
34. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60